A University of Alberta spinoff company has received FDA approval for an artificial intelligence tool that could revolutionize thyroid ultrasounds, making the procedure faster and easier for thousands of Canadians who undergo it each year.MEDO.ai, wi
Share this article
Share this article
EDMONTON, AB, May 6, 2021 /PRNewswire/ - Medo, an artificial intelligence technology start-up company headquartered in Singapore and Canada, is pleased to announce that it has received 510(k) clearance from the U.S. Food and Drug Administration for the world s first tool using Artificial Intelligence to drastically simplify the Thyroid ultrasound scanning workflow. The company previously
announced the release of an AI assistant for helping diagnose hip dysplasia and is now expanding their technology into other use cases.
Over 1.5 million thyroid ultrasound exams are done each year in the USA alone. This high volume is due to the fact that lumps, or nodules on the thyroid gland are common and although usually benign, can be cancerous. Each ultrasound exam is non-invasive and safe, but incredibly time consuming and potentially error-prone, involving a tedious review of hundreds of images to locate and measure thyroid nodules individually. T